The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
Non-small-cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–257 of 257
Exhaled breath condensate biomarkers for lung cancer
Campanella, A., Summa, S. D., & Tommasi, S. (2019) · Journal of Breath Research · doi:10.1088/1752-7163/ab2f9f · Cited by 85
Peters, S., Dafni, U. G., Boyer, M. J., Ruysscher, D. D., Finn, C. F., Felip, E., Garrido, P., Girard, N., Gückenberger, M., Haanen, J. B. A. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy553 · Cited by 82
Self-citationBradley, J. D., Sugawara, S., Lee, K. H., Ostoros, G., Demirkazık, A., Zemanová, M., Sriuranpong, V., Gelatti, A. C. Z., Menezes, J. J. D., Żurawski, B. A., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102986 · Cited by 80
Diagnosing Non-Small Cell Lung Cancer by Exhaled Breath Profiling Using an Electronic Nose
Kort, S., Brusse-Keizer, M. G. J., Schouwink, H., Citgez, E., de Jongh, F. H., van Putten, J. W. G., van den Borne, B., Kastelijn, E. A., Stolz, D., Schuurbiers, M. M. F., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.09.042 · Cited by 78
Mok, T. S. K., Yao, W., Duruisseaux, M., Doucet, L., Martínez, A. A., Gregorc, V., Juan-Vidal, O., Lu, S., Bondt, C. D., de Marinis, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.17_suppl.lba8509 · Cited by 76
Self-citationGantzer, J., Davidson, G., Vokshi, B., Weingertner, N., Bougoüin, A., Moreira, M., Lindner, V., Lacroix, G., Mascaux, C., Chenard, M., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac040 · Cited by 75
Koller, M. T., Hjermstad, M. J., Tomaszewski, K. A., Tomaszewska, I. M., Hornslien, K., Harle, A. S. M., Arrarás, J. I., Morag, O., Pompili, C., Ioannidis, G., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx453 · Cited by 74
Triphuridet, N., Zhang, S. S., Nagasaka, M., Gao, Y., Zhao, J. J., Syn, N. L. X., Hanaoka, T., Ou, S. I., & Shum, E. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.094 · Cited by 70
Implementing Lung Cancer Screening in Europe: Taking a Systems Approach
Wait, S., Álvarez-Rosete, A., Osama, T., Bancroft, D., Cornelissen, R., Marušić, A., Garrido, P., Adamek, M., van Meerbeeck, J. P., Snoeckx, A., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100329 · Cited by 68
Yang, J. C., Han, B., Jimenez, E. D. L. M., Lee, J.-S., Koralewski, P., Karadurmuş, N., Sugawara, S., Livi, L., Basappa, N. S., Quantin, X., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.023 · Cited by 68
Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008189 · Cited by 65
Wirth, L. J., Brose, M. S., Subbiah, V., Worden, F. P., Solomon, B., Robinson, B. G., Hadoux, J., Tomasini, P., Weiler, D., Deschler-Baier, B., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02503 · Cited by 65
Self-citationSuh, Y. J., Lee, H.-J., Sung, P., Yoen, H., Kim, S. W., Han, S., Park, S., Hong, J. H., Kim, H., Lim, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.221 · Cited by 64
Role of randomized phase III trials in an era of effective targeted therapies
Sharma, M. R., & Schilsky, R. L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.190 · Cited by 63
Lam, V. K. L., Tran, H. T., Banks, K. C., Lanman, R. B., Rinsurongkawong, W., Peled, N., Lewis, J., Lee, J. J., Roth, J. A., Roarty, E. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.020 · Cited by 63
Self-citationScreening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer
Silva, M., Galeone, C., Sverzellati, N., Marchianò, A. V., Calareso, G., Sestini, S., Vecchia, C. L., Sozzi, G., Pelosi, G., & Pastorino, U. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.014 · Cited by 58
Mezquita, L., Jové, M., Nadal, E., Kfoury, M., Morán, T., Ricordel, C., Dhooge, M., Tlemsani, C., Léna, H., Teulé, À., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.005 · Cited by 58
Hobor, S., Bakir, M. A., Hiley, C. T., Skrzypski, M. T., Frankell, A. M., Bakker, B., Watkins, T. B. K., Markovets, A. A., Dry, J. R., Brown, A. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47606-9 · Cited by 58
Self-citationErnst, S. M., Mankor, J. M., van Riet, J., von der Thüsen, J. H., Dubbink, H. J., Aerts, J. G. J. V., de Langen, A. J., Smit, E. F., Dingemans, A. C., & Monkhorst, K. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.030 · Cited by 51
Cui, X., Zheng, S., Heuvelmans, M. A., Du, Y., Sidorenkov, G. A., Fan, S., Li, Y., Xie, Y., Zhu, Z., Dorrius, M. D., et al. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.110068 · Cited by 48
Reck, M., Nadal, E., Girard, N., Filippi, A. R., Martin, L. W., Gay, C. M., Petersen, C., Gale, D. G., Emeribe, U. A., Georgoulia, N., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.06.007 · Cited by 47
Self-citationMolecular abnormalities in lung carcinogenesis and their potential clinical implications
Li, M. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00341-5 · Cited by 44
Lung Cancer Mortality in the Lung Screening Study Feasibility Trial
Doroudi, M., Pinsky, P. F., & Marcus, P. M. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky042 · Cited by 44
Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 43
Wang, Y., Kondrat, K., Adhikari, J., Nguyen, Q., Yu, Q., & Uprety, D. (2024) · Cancer · doi:10.1002/cncr.35476 · Cited by 41
Jun, S., Shukla, N. A., Durm, G. A., Hui, A. B., Cao, S., Ganti, A. K., Jabbour, S. K., Kunder, C. A., Alizadeh, A. A., Hanna, N. H., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.06.024 · Cited by 40
Robbins, H. A., Alcala, K., Moez, E. K., Guida, F., Thomas, S., Zahed, H., Warkentin, M. T., Smith‐Byrne, K., Brhane, Y., Muller, D. C., et al. (2022) · Annals of Epidemiology · doi:10.1016/j.annepidem.2022.10.014 · Cited by 38
Pezzuto, F., Hofman, V., Bontoux, C., Fortarezza, F., Lunardi, F., Calabrese, F., & Hofman, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107249 · Cited by 37
Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective
Bucknell, N. W., Belderbos, J. S. A., Palma, D. A., Iyengar, P., Samson, P. P., Chua, K. L. M., Gomez, D. R., McDonald, F., Louie, A. V., Finn, C. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.003 · Cited by 36
Kan, C. F. K., Unis, G. D., Li, L. Z., Gunn, S., Li, L., Soyer, H. P., & Stark, M. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.555331 · Cited by 35
Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer
Wang, C.-L., Hsu, K.-H., Chang, Y.-H., Ho, C., Chiang, C., Chen, K., Cheung, Y., Huang, P.-C., Chen, Y., Chen, C.-Y., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.018 · Cited by 32
Billingy, N. E., Tromp, V. N. M. F., Aaronson, N. K., Hoek, R. J. A., Bogaard, H. J., Onwuteaka-Philipsen, B. D., van de Poll-Franse, L. V., Hugtenburg, J. G., Belderbos, J. S. A., Becker‐Commissaris, A., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad159 · Cited by 32
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal
Bestvina, C. M., Garassino, M. C., Neal, J. W., Wakelee, H. A., Diehn, M., & Vokes, E. E. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00258 · Cited by 31
Self-citationFares, A. F., Li, Y., Jiang, M., Brown, M. C., Lam, A. C. L., Aggarwal, R., Schmid, S., Leighl, N. B., Shepherd, F. A., Wang, Z., et al. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00131-7 · Cited by 30
Madas, B. G., Boei, J. J. W. A., Fenske, N., Hofmann, W. E., & Mezquita, L. (2022) · Radiation and Environmental Biophysics · doi:10.1007/s00411-022-00998-y · Cited by 26
Early Detection of Lung Cancer Using Small RNAs
Sikosek, T., Horos, R., Trudzinski, F. C., Jehn, J., Frank, M., Rajakumar, T., Klotz, L. V., Mercaldo, N. D., Kahraman, M., Heuvelman, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.005 · Cited by 26
Self-citationChang, J. C., & Rekhtman, N. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100453 · Cited by 26
Rane, J. K., Frankell, A. M., Weeden, C. E., & Swanton, C. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0469 · Cited by 25
Reck, M., Ciuleanu, T., Cobo, M., Schenker, M., Żurawski, B. A., Menezes, J. J. D., Richardet, E., Bennouna, J., Felip, E., Juan, Ó., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.015 · Cited by 23
Self-citationLung Screen Uptake Trial: results from a single lung cancer screening round
Ruparel, M., Quaife, S. L., Dickson, J. L., Horst, C., Tisi, S., Hall, H., Taylor, M. N., Ahmed, A., Shaw, P. J., Burke, S. J., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2020-214703 · Cited by 22
Prelaj, A., Ganzinelli, M., Trovò, F., Roisman, L. C., Pedrocchi, A., Kosta, S., Restelli, M., Ambrosini, E., Broggini, M., Pravettoni, G., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.02.005 · Cited by 22
Self-citationGermline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History
Oxnard, G. R., Nguyen, K.-S. H., & Costa, D. B. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt361 · Cited by 20
Carcinogenesis and lung cancer: 70 years of progress and more to come
Samet, J. M. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa094 · Cited by 18
Progress and Outlook on Electrochemical Sensing of Lung Cancer Biomarkers
Zheng, R., Wu, A., Li, J., Tang, Z., Zhang, J., Zhang, M., & Wei, Z. (2024) · Molecules · doi:10.3390/molecules29133156 · Cited by 17
Dejima, H., Hu, X. Y., Chen, R., Zhang, J., Fujimoto, J., Parra, E. R., Haymaker, C., Hubert, S. M., Duose, D. Y., Solis, L. M., et al. (2020) · medRxiv · doi:10.1101/2020.07.11.20142992 · Cited by 16
Self-citationImmune surveillance in clinical regression of pre-invasive squamous cell lung cancerPreprint
Pennycuick, A., TEIXEIRA, V. H., AbdulJabbar, K., Raza, S. E. A., Lund, T., Akarca, A. U., Rosenthal, R., Pipinikas, C., Lee-Six, H., Chandrasekharan, D. P., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/833004 · Cited by 14
Screening approaches for lung cancer by blood-based biomarkers: Challenges and opportunities
van den Broek, D. A., & Groen, H. J. M. (2023) · Tumor Biology · doi:10.3233/tub-230004 · Cited by 14
Metabolomics-based search for lung cancer markers among patients with different smoking status
Klupczyńska, A., Daskalaki, E., Wheelock, C. E., Kasprzyk, M., Dyszkiewicz, W., Grabicki, M., Brajer-Luftmann, B., Pawlak, M., Kokot, Z. J., & Matysiak, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-65835-2 · Cited by 14
Lariscy, J. T., Hummer, R. A., & Rogers, R. G. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.03.008 · Cited by 13
Cannabis use and lung cancer: time to stop overlooking the problem?
Betser, L., Glorion, M., Mordant, P., Caramella, C., Ghigna, M., Besse, B., Planchard, D., Pavec, J. L., Chapelier, A. R., Friard, S., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04132-2020 · Cited by 13
Owen, D. H., Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Florez, N., Puri, S., Schenk, E. L., Schneider, B. J., & Patel, J. D. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00177 · Cited by 13
Facing an un-met need in lung cancer screening: The never smokers
Arrieta, O. G., Arroyo‐Hernández, M., Soberanis-Piña, P. D., Viola, L., Re, M. D., Russo, A., de Miguel‐Pérez, D., Cardona, A. F., & Rolfo, C. D. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104436 · Cited by 13
The mutagenic forces shaping the genomic landscape of lung cancer in never smokersPreprint
Díaz‐Gay, M., Zhang, T., Hoang, P. H., Khandekar, A., Zhao, W., Steele, C. D., Otlu, B., Nandi, S. P., Vangara, R., Bergstrom, E. N., et al. (2024) · medRxiv · doi:10.1101/2024.05.15.24307318 · Cited by 12
Surapaneni, M., & Uprety, D. (2023) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.73042 · Cited by 11
Emerging Strategies in Lung Cancer Screening: Blood and Beyond
Bhalla, S., Yi, S., & Gerber, D. E. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad137 · Cited by 11
Discrimination Between Primary Lung Cancer and Lung Metastases by Genomic Profiling
Higuchi, R., Goto, T., Nakagomi, T., Hirotsu, Y., Oyama, T., Amemiya, K., Mochizuki, H., & Omata, M. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100255 · Cited by 8
Zhang, J. J., Hu, X., Zhu, B., Vokes, N. I., Fukuoka, J., Alvarez, F. R. R., Heeke, S., Moreira, A. L., Solis, L. M., Haymaker, C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4396272/v1 · Cited by 3
Self-citation
Research works printed but not linked: 28
- World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use 2000–2025, fourth edition (WHO, 2021).
- Akhtar-Danseh, G. G., Akhtar-Danesh, N. & Finley, C. Uptake and survival effects of minimally invasive surgery for lung cancer: a population-based study. Eur. J. Surg. Oncol. 47, 1791–1796 (2021). · doi:10.1016/j.ejso.2021.01.002
- WHO Classification of Tumours Editorial Board. Thoracic Tumours, WHO Classification of Tumours 5th edn, Vol. 5 (WHO, 2021).
- Kerr, K. M. in Molecular Pathology of Lung Cancer (eds. Cagle, P. T. et al.) 35–52 (Springer, 2012). A key overview of the molecular classification of lung cancer. · doi:10.1007/978-1-4614-3197-8_5
- Minna, J. D., Fong, K., Zöchbauer-Müller, S. & Gazdar, A. F. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 8, S41–S46 (2002).
- Amin, M. et al. AJCC Cancer Staging Manual 8th edn (Springer, 2017).
- Hendriks, L. E. et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 339–357 (2023). European Society for Medical Oncology recommendations on the management of oncogene-addicted NSCLC. · DOI · Paper page
- Poon, C., Wilsdon, T., Sarwar, I., Roediger, A. & Yuan, M. Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Front. Public Health 11, 1264342 (2023). · doi:10.3389/fpubh.2023.1264342
- Hanash, S. M., Ostrin, E. J. & Fahrmann, J. F. Blood based biomarkers beyond genomics for lung cancer screening. Transl. Lung Cancer Res. 7, 327–335 (2018). · doi:10.21037/tlcr.2018.05.13
- Heiden, B. T. et al. Association between surgical quality metric adherence and overall survival among US veterans with early-stage non-small cell lung cancer. JAMA Surg. 158, 293–301 (2023). · doi:10.1001/jamasurg.2022.6826
- Whitson, B. A., D’Cunha, J. & Maddaus, M. A. Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression. Med. Hypotheses 68, 1328–1332 (2007). · doi:10.1016/j.mehy.2006.09.063
- Veronesi, G. et al. Robotic resection of Stage III lung cancer: an international retrospective study. Eur. J. Cardiothorac. Surg. 54, 912–919 (2018). · doi:10.1093/ejcts/ezy166
- Savonitto, E., Yasufuku, K. & Wallace, A. M. Robotic segmentectomy for early-stage lung cancer. Front. Surg. 10, 1090080 (2023). · doi:10.3389/fsurg.2023.1090080
- Veronesi, G. et al. Perioperative outcome of robotic approach versus manual videothoracoscopic major resection in patients affected by early lung cancer: results of a randomized multicentric study (ROMAN study). Front. Oncol. 11, 726408 (2021). · doi:10.3389/fonc.2021.726408
- Patel, Y. S. et al. RAVAL trial: protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. PLoS ONE 17, e0261767 (2022). · doi:10.1371/journal.pone.0261767
- Houda, I. et al. OA06.03. An international EORTC survey on resectability of stage III non-small cell lung cancer. J. Thorac. Oncol. 18, S55–S56 (2023). · doi:10.1016/j.jtho.2023.09.044
- Dingemans, A. M. et al. OA06.05. Consensual definition of stage III NSCLC resectability: EORTC-lung cancer group initiative with other scientific societies. J. Thorac. Oncol. 18, S57–S58 (2023). · doi:10.1016/j.jtho.2023.09.046
- Perez, C. A. et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45, 2744–2753 (1980). · doi:10.1002/1097-0142(19800601)45:11<2744::aid-cncr2820451108>3.0.co;2-u
- Filippi, A. R. R. et al. LBA62. Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): primary results from the DUART study. Ann. Oncol. 34, S1302 (2023). · doi:10.1016/j.annonc.2023.10.058
- Ko, R. et al. 1292MO. A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A. Ann. Oncol. 34, S745–S746 (2023). · doi:10.1016/j.annonc.2023.09.770
- Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358–376 (2023). · DOI · Paper page
- Genentech. Genentech reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. gene.com https://www.gene.com/media/press-releases/14951/2022-05-10/genentech-reports-interim-results-for-ph (2022).
- Neal, J. et al. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. J. Thorac. Oncol. 18, S39–S40 (2023). · doi:10.1016/s1556-0864(23)00260-5
- Paz-Ares, L. et al. 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3 L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results. Ann. Oncol. 32, S953–S954 (2021). · doi:10.1016/j.annonc.2021.08.1799
- Ahn, M. J. et al. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Ann. Oncol. 34, S1305–S1306 (2023). · doi:10.1016/j.annonc.2023.10.061
- Sanofi announces end of program evaluating tusamitamab ravtansine after a 2 L NSCLC phase 3 trial did not meet a primary endpoint. Sanofi https://www.sanofi.com/en/media-room/press-releases/2023/2023-12-21-06-30-00-2799759 (2023).
- Camidge, D. R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: primary analysis of the LUMINOSITY trial. J. Clin. Oncol. 42, 103–103 (2024). · doi:10.1200/jco.2024.42.16_suppl.103
- Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst. Rev. 5, CD007309 (2010). A Cochrane Review providing confirmation of the efficacy of chemotherapy in advanced NSCLC.
Cited by
Zheng, Q., Liu, Y., Li, T., Zhang, X., Geng, Y., Chen, Z., Zhou, J., Fan, W., Wang, Y., Zhang, L., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1871582
Metadata
- Authors
- Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M.
- Venue
- Nature Reviews Disease Primers
- Published
- 2024-09-26
- Volume
- 10
- Issue
- 1
- Pages
- 71-71
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4402886999
- Cited by
- 568
- References
- 257
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-01-07)
- Open access
- green
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.